BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250213T160000
DTEND;TZID=Europe/Stockholm:20250213T170000
DTSTAMP:20260429T205859
CREATED:20250117T160857Z
LAST-MODIFIED:20250207T131544Z
UID:33984-1739462400-1739466000@senzagen.com
SUMMARY:Webinar: Overcoming the challenges of testing Natural Extracts with GARD technology
DESCRIPTION:Join SenzaGen and industry leaders from Clarins and Bic Skin Creative for an in-depth webinar on using GARD® assays for skin sensitization testing.  \nLearn how this innovative technology overcomes the unique challenges of testing complex Natural Extracts\, which often fall outside the scope of traditional methods in OECD 442E Test Guidelines. \nThrough case studies\, we will showcase how GARD® has supported the safety assessment of natural extract-based products\, providing reliable solutions for today’s testing needs. \n \nKey learnings and highlights\n\nChallenges of testing complex natural extracts with conventional methods.\nHow the GARD® technology brings new opportunities to the field of skin sensitization.\nCase studies from Clarins and Bic Skin Creative on applying GARD® for natural extract safety assessments.\n\nAgenda and speakers\n1. Advancing skin sensitization testing with GARD®: Spotlight on Natural Extracts\n \nAndy Forreryd\, PhD\nScientific Liaison @ SenzaGen \nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning\, engaging in collaborations with industry leaders to investigate novel applications for NAM-based sensitization testing\, with the aim to replace the need for animal studies. He is co-developer of the GARDskin assay (OECD TG 442) for the assessment of chemical sensitizers. \n2. Safety assessment of raw materials extracted from plants using GARD®\n \nMylène Landais\nSafety Assessor @ Clarins \nMylène Landais is a toxicology expert currently working for the Clarins Group as an ingredient and formulas safety assessment project manager. She holds a master’s degree in toxicology and\, with 10 years of experience in the cosmetic industry\, mainly works on the safety assessment and risk assessment of finished products and ingredients such as plant extracts and synthetic ingredients. \nThis role is key to ensure the safety of cosmetic products consumers by using alternative to animal testing methods while complying with the main regulations worldwide and facing new challenges\, such as the new Chinese cosmetic regulation. \n3. Assessing skin sensitization potential of new skin-binding dyes using the GARD®skin Dose-Response assay\n \nIan Mallov\nManager of Scientific Research @ Bic Skin Creative \nIan Mallov is manager of scientific research at Bic Skin Creative. Ian grew up in Truro\, Nova Scotia\, Canada and holds a Ph.D. in inorganic chemistry from the University of Toronto. He began as an industrial postdoctoral researcher in the lab of Prof. Chris Caputo at York University with Toronto-based start-up Inkbox Ink. As Inkbox was acquired by Bic\, his role shifted to focus on assessing the efficacy and toxicology of derivatives of natural skin-binding dyes. In his spare time\, he enjoys writing\, running\, and ice hockey. Ian lives in Halifax\, Nova Scotia with his wife and six-month-old daughter. \nWhat are Natural Extracts?\nNatural extracts are are ingredients derived from natural sources like plants and herbs. They are often classified as UVCBs (Unknown or Variable composition\, Complex reaction products\, or Biological materials). These complex substances present unique testing challenges and frequently fall outside the applicability domains of conventional in vitro assays included in OECD Test Guideline for skin sensitization assessment. \n  \n \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording.
URL:https://senzagen.com/event/webinar-natural-extracts/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241120T160000
DTEND;TZID=Europe/Stockholm:20241120T170000
DTSTAMP:20260429T205859
CREATED:20241105T080455Z
LAST-MODIFIED:20241105T094128Z
UID:33676-1732118400-1732122000@senzagen.com
SUMMARY:Webinar: In vitro skin sensitization testing: Ensuring conclusive results for challenging samples
DESCRIPTION:Join us for a special re-run of our popular GARD® webinar to explore the recent advancement in Skin Sensitization testing\, focusing on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. \nOur skin sensitization experts will address challenges posed by various “Difficult-to-Test” substances\, discussing the applicability domain of key event-based NAMs and existing test strategies. \nYou will learn about the broad applicability of GARD®skin (OECD TG442E) as we review scientific data on challenging substances and exciting projects done in collaboration with industry partners: \nAgrochemical Formulations | Formulated Lubricant Products | Indirectly Acting Haptens | Metals | Natural Extracts | Polymers | UVCBs \nRecorded webinar with live Q&A\nThis recorded webinar will last approximately 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey takeaways\n\nNAMs and test strategies for skin sensitization testing of challenging samples.\nThe applicability domain of GARD®skin for challenging substances and its integration into Defined Approaches.\nCase studies on Agrochemical Formulations\, Formulated Lubricant Products\, Indirectly Acting Haptens\, Metals\, Natural Extracts\, Polymers\, and UVCBs.\n\nWhat are challenging /“difficult-to-test” substances?\nIn the context of skin sensitization testing\, certain groups of chemicals are considered difficult to test using conventional cell-based methods. Examples of commonly recognised “difficult-to-test” samples include indirectly acting haptens\, complex mixtures\, and substances with low water solubility. \nRead more about difficult-to-test substances. \nSpeaker\n \n  \n \n 
URL:https://senzagen.com/event/webinar-spotlight-on-challenging-samples/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/11/BANNER-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241031
DTSTAMP:20260429T205859
CREATED:20240905T122507Z
LAST-MODIFIED:20250317T085918Z
UID:33088-1730073600-1730332799@senzagen.com
SUMMARY:ASCCT 13th Annual Meeting
DESCRIPTION:Meet us at the American Society for Cellular and Computational Toxicology (ASCCT) Annual Meeting in Research Triangle Park\, North Carolina. \n  \nOral presentation | Monday\, 28 October | 17:20-17:35\nNAMs for botanical safety evaluation: Case Study on Determine the Safe Use Levels of Genipa Plant Extract in Temporary Tattoo Ink with GARD®\n  \nPoster\nGARD®skin Dose-Response for skin sensitizing potency assessment: Performance on the Reference Chemical Potency List (RCPL)
URL:https://senzagen.com/event/ascct-13th-annual-meeting/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/24050-RAD-ASCCT-13th-Annual-Meeting-Graphics-1584x39676_Page_1-scaled-e1725539063290.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241009T160000
DTEND;TZID=Europe/Stockholm:20241009T170000
DTSTAMP:20260429T205859
CREATED:20240905T141518Z
LAST-MODIFIED:20240924T125128Z
UID:33109-1728489600-1728493200@senzagen.com
SUMMARY:Webinar: Advancing NAMs for Skin Sensitization Testing
DESCRIPTION:Spotlight on Point-of-Departure\, Challenging Substances\, and Active Ingredients\nWe invite you to join our upcoming webinar\, where industry leaders from Lundbeck\, Unilever\, and Cargill\, along with experts from SenzaGen will explain the latest advancements in skin sensitization testing. \nJoin us as we explore the latest data from our GARD® platform on skin sensitization and gain insights from leading industry experts. We will also highlight case studies from collaborative projects\, including those with L’Oréal and ExxonMobil Biomedical Sciences. \nIf you missed SenzaGen’s scientific presentations at Eurotox this year\, this webinar is your chance to catch up on the most recent developments. \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey topics\n\nDifficult-to-Test Samples\nUVCBs and Formulated Lubricant Products\nHydrophobic Esters\nDrug products and Active Substances\nPoint-of-Departure for Quantitative Risk Assessment\nDefined Approaches\nIndustry collaborations: Case studies and publications\n\nDon’t miss out on this opportunity to gain valuable insights and network with experts in the field! \nSpeakers\n \n \n \n \n \n 
URL:https://senzagen.com/event/webinar2024eurotoxhighlights/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/FINAL-Eurotox-sep-2024-1200x1200px-1-e1727179193578.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240908T080000
DTEND;TZID=Europe/Stockholm:20240911T170000
DTSTAMP:20260429T205859
CREATED:20240126T092505Z
LAST-MODIFIED:20240905T105818Z
UID:31912-1725782400-1726074000@senzagen.com
SUMMARY:Eurotox 2024
DESCRIPTION:Meet us at Booth #56\nCome meet us at booth #56 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps in skin sensitizing hazard and quantitative potency assessment. Additionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \n  \n \nIndustry-Hosted Session\n“Advancing NAMs for Skin Sensitization” \nGuest speakers from Lundbeck and Unilever\n \nPosters\nSpotlight on Hydrophobic Esters\, PoD\, Defined Approaches\, and more\n🎫 P01-79 #996 | Joint poster with Cargill\nThe applicability of GARD®skin for assessing skin sensitization potential of hydrophobic esters during product development \n🎫 P19-57 #661 | Joint poster with L’Oréal\nImproved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 P19-75 #840 | Joint poster with Sonova\nIntegrating NAMs into early-stage screening of novel materials intended for use in Medical Devices: Case studies on the use of GARD® for in vitro skin sensitization assessment \n🎫 P20-17 #613 | SenzaGen poster\nGARD®skin as a drop-in replacement KE3-method in OECD GD 497 Defined Approaches \n🎫 P23-21 #937 | ToxHub poster\nWorkflow for Occupational Exposure Limit Determination and Banding: Focus on Skin and Respiratory Sensitization using NAMs approaches \n🎫 LP-28 | ToxHub poster\nRisk Assessment Approaches for Nanomaterials in Medical Devices \n 
URL:https://senzagen.com/event/eurotox2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/Lime-banner-new-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240627T160000
DTEND;TZID=Europe/Stockholm:20240627T170000
DTSTAMP:20260429T205859
CREATED:20240521T140048Z
LAST-MODIFIED:20240613T062934Z
UID:32293-1719504000-1719507600@senzagen.com
SUMMARY:Webinar: Meta-analysis of GARD® data\, 200+ chemicals
DESCRIPTION:Spotlight on in vitro quantitative assessment of skin sensitizing potency.\nJoin our upcoming webinar to explore the recent advancement in GARD® for quantitative assessment of skin sensitizing potency.  \nThis session will present a meta-analysis of GARD® data covering over 200 chemicals\, including three blinded datasets generated in collaboration with industry partners. \nThese data will demonstrate how GARD® can estimate a Point of Departure (PoD) and be incorporated into downstream strategies for Quantitative Risk Assessment (QRA)\, contributing to the assessment of safe use levels of chemicals. \nYou will learn how the assay can be used to predict LLNA EC3 values\, Human NOELs\, and GHS/CLP classifications (1A or 1B). \nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey topics\n\nAn introduction to the prediction model\, genomics\, and machine learning technology.\nThe GARD® assay’s performance in predicting PoD for QRA.\nHow the GARD® assay ensures the safe use of ingredients in consumer products.\n\nSpeakers\n \n 
URL:https://senzagen.com/event/webinar-meta-analysis-of-gard-data/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240612T080000
DTEND;TZID=Europe/Stockholm:20240614T170000
DTSTAMP:20260429T205859
CREATED:20240126T094148Z
LAST-MODIFIED:20240126T094148Z
UID:31924-1718179200-1718384400@senzagen.com
SUMMARY:ITCASS and ERGECD meeting 2024
DESCRIPTION:Meet us in Liverpool at the the 11th meeting of Immunotoxicology & Chemical Allergy (ITCASS) and the 30th meeting of European Research Group on Experimental Contact Dermatitis (ERGECD).
URL:https://senzagen.com/event/itcass-and-ergecd-meeting-2024/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240603T080000
DTEND;TZID=Europe/Stockholm:20240606T170000
DTSTAMP:20260429T205859
CREATED:20240126T091543Z
LAST-MODIFIED:20240521T140249Z
UID:31906-1717401600-1717693200@senzagen.com
SUMMARY:ESTIV Congress 2024
DESCRIPTION:Come meet us at booth #22 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment.  \nAdditionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \nPresentations and Posters\nOur team will showcase several posters and presentations. Dive into new scientific data and discover exciting projects done in collaboration with industry partners. \nTuesday 09:00-10:30 | Presentation in Session 2b\nProject in collaboration with L’Oreal. “Improved confidence of quantitative sensitizing potency assessment for PoD using GARD®skin Dose-Response”\n\nThursday 11:30-12:45 | Presentation in Session 9a\n“Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment” \nPoster | Presented by ToxHub\n#334 | “Integrated Risk Assessment and Compliance Strategies for Nanomaterials in Medical Devices”
URL:https://senzagen.com/event/estiv-congress-2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/ESTIV-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240529T090000
DTEND;TZID=Europe/Stockholm:20240530T170000
DTSTAMP:20260429T205859
CREATED:20240521T135437Z
LAST-MODIFIED:20240527T133353Z
UID:32280-1716973200-1717088400@senzagen.com
SUMMARY:Cosmetotest
DESCRIPTION:Program\n‘Introduction to GARDskin (OECD TG 442E) for evaluation of skin sensitization hazard with dose-response option for quantitative risk assessment’\nDate: 30/05\nSession 1: Safety: from irritation to sensitization\nPresenter: Andy Forreryd\, SenzaGen \nBooth: #21
URL:https://senzagen.com/event/cosmetotest/
LOCATION:ENS Lyon\, France
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/05/LinkedIn-banner-v1-e1716816802689.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240423T160000
DTEND;TZID=Europe/Stockholm:20240423T170000
DTSTAMP:20260429T205859
CREATED:20240321T085330Z
LAST-MODIFIED:20240325T130110Z
UID:32117-1713888000-1713891600@senzagen.com
SUMMARY:Webinar: Advancing NAMs for Skin Sensitization Testing
DESCRIPTION:Spotlight on Applicability Domain\, Quantitative Potency Assessment and Medical Devices\nIn case you missed SenzaGen’s poster presentations and scientific session at this year’s SOT\, we are pleased to offer you a new opportunity to participate on April 23\, 2024! \nIn this webinar Dr Andy Forreryd\, SenzaGen’s in vitro toxicology expert\, will summarize the latest GARD data from industry collaborations: \nCorteva Agriscience | ExxonMobil Biomedical Sciences | L’Oréal | IFF | RIFM | Inotiv | Johnson Matthey | Sonova | Duearity \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey topics\n\nAgrochemical Formulations\nUVCBs and Formulated Lubricant Products\nComplex Mixtures\nMetals\nPoD for Quantitative Risk Assessment\nNESILs for Fragrance Materials\nRegulatory Acceptance According to MDR\nEarly-stage screening of materials intended for use in Medical Devices\n\nSpeakers\n \n  \n \n 
URL:https://senzagen.com/event/webinar-advancing-nams-for-skin-sensitization-testing/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/03/Lime_webinar-final.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240310T080000
DTEND;TZID=Europe/Stockholm:20240314T170000
DTSTAMP:20260429T205900
CREATED:20231115T134814Z
LAST-MODIFIED:20240306T094116Z
UID:31573-1710057600-1710435600@senzagen.com
SUMMARY:2024 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #732\nDiscuss your testing needs with us\n  \nExhibitor-Hosted Session\nExpert round table on NAMs and industry trends\nTuesday\, 12 Mar | 9:00 am-10:00 am\n \n \nPosters\nSpotlight on PoD\, NESILs\, product development and CE-marking of Medical Devices\nMonday\, 11 Mar | 9:15 am-11:15 am\n🎫 Joint poster with Sonova\nP487 #3362 | Unveiling skin sensitizing potential: case studies on biocompatible material development utilizing the in vitro GARD®skin Medical Device assay \n🎫 Joint poster with Duearity\nP480 #3355 | Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment \n🎫 Joint poster presented by RIFM\nP318 #3205 | Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARD®skin Dose-Response assay \nTuesday\, 12 Mar | 2:15 pm-4:15 pm\n🎫 Joint poster with L’Oréal\nP739 #4190 | Improved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 Joint poster presented by IFF\nP762 #4213 | A Next Generation Risk Assessment (NGRA) Framework to conduct Quantitative Risk Assessment (QRA2) to determine safe use levels of fragrance ingredients in cosmetic products \n🎫 Joint poster presented by Inotiv\nP738 #4189 | Testing of Regulatory-Relevant Chemicals for Skin and Respiratory Sensitization Hazard \n\n 
URL:https://senzagen.com/event/sot-annual-meeting-2024-toxexpo/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/11/SOT2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240207T160000
DTEND;TZID=Europe/Stockholm:20240207T170000
DTSTAMP:20260429T205900
CREATED:20240116T102331Z
LAST-MODIFIED:20240116T145019Z
UID:31853-1707321600-1707325200@senzagen.com
SUMMARY:Webinar: Spotlight on Difficult-to-Test samples
DESCRIPTION:Join our upcoming webinar to explore the recent advancement in GARD® for Skin Sensitization assessment\, with a specific focus on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. \nOur skin sensitization experts will address challenges posed by various Difficult-to-Test substances\, discussing the applicability domain of key event-based NAMs and existing test strategies. \nYou will learn about the broad applicability of GARD®skin OECD TG442E as we present scientific data on Difficult-to-Test substances and exciting projects done in collaboration with industry partners: \nAgrochemical Formulations | Formulated Lubricant Products | Indirectly Acting Haptens | Metals | Natural Extracts | Polymers | UVCBs  \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey takeaways\n\nNAMs and test strategies for skin sensitization testing of Difficult-to-Test samples.\nThe applicability domain of GARD®skin for challenging substances and its integration into Defined Approaches.\nCase studies on Agrochemical Formulations\, Formulated Lubricant Products\, Indirectly Acting Haptens\, Metals\, Natural Extracts\, Polymers\, and UVCBs.\n\nWhat are “difficult-to-test” substances?\nIn the context of skin sensitization testing\, certain groups of chemicals are considered difficult to test using conventional cell-based methods. Examples of commonly recognised “difficult-to-test” samples include indirectly acting haptens\, complex mixtures\, and substances with low water solubility. \nRead more about difficult-to-test substances. \nSpeakers\n \n  \n \n 
URL:https://senzagen.com/event/webinar-spotlight-on-difficult-to-test-samples/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/banner-website-v5-with-dates-1-e1705416604964.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231214T160000
DTEND;TZID=Europe/Stockholm:20231214T170000
DTSTAMP:20260429T205900
CREATED:20231114T150216Z
LAST-MODIFIED:20231121T211556Z
UID:31504-1702569600-1702573200@senzagen.com
SUMMARY:Webinar: Safety of acrylate monomers\, metals\, and other materials used in medical device development
DESCRIPTION:Join our upcoming free webinar to explore the effective utilization of in vitro methods for safety assessment of materials during product development of Medical Devices.\nWe will discuss recent advancements in in vitro methods for assessing the endpoints of skin irritation and skin sensitization. Learn how to integrate these assessments into your product development process as a complement to chemical characterization and cytotoxicity testing. \nDiscover how this approach can aid in: \nSelecting the right material | Developing new materials | Optimizing production | Choosing the appropriate sterilization method\n\nKey takeaways\n\n*Gain insights into the key fundamentals of the biological evaluation of medical devices and the availability of in vitro biocompatibility testing. \n*Explore the applicability of the in vitro GARD technology in the assessment of medical devices\, supporting both polar and non-polar extraction vehicles (ISO 10993-12). \n*Examine user cases illustrating the safety assessment of acrylate monomers\, metals\, and various materials utilized in medical device development. Learn how these assessments contribute to material selection and production optimization. \n\nSpeakers\n\n \n 
URL:https://senzagen.com/event/webinar-safety-of-acrylate-monomers-metals-and-other-materials-used-in-medical-device-development/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/11/Webinar-banner-v10-without-date_MD-product-development.png.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231116
DTEND;VALUE=DATE:20231118
DTSTAMP:20260429T205900
CREATED:20230824T072405Z
LAST-MODIFIED:20231108T143625Z
UID:30942-1700092800-1700265599@senzagen.com
SUMMARY:Annual Medical Device Biocompatibility Conference
DESCRIPTION:Presentation \n\nThe GARD®skin Medical Device assay for assessing the skin sensitizing potential of medical devices: A case study on the use of in vitro data in the biological evaluation for CE marking according to MDR\n\nKey Points \n\nA proof-of-concept study using the GARD®skin Medical Device assay to evaluate the skin sensitizing potential of medical device materials according to ISO 10993-10.\nA case study using in vitro data for the endpoints of cytotoxicity\, skin irritation and skin sensitization in the biological evaluation for CE-marking according to MDR to avoid animal testing while accelerating time to market.
URL:https://senzagen.com/event/annual-medical-device-biocompatibility-conference/
LOCATION:Berlin\, Germany
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/bicompatibility_berlin.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20260429T205900
CREATED:20230824T070701Z
LAST-MODIFIED:20231109T141151Z
UID:30935-1699747200-1700092799@senzagen.com
SUMMARY:ACT 2023 Annual Meeting
DESCRIPTION:→ Booth #333\nSpotlight on difficult-to-test samples and in vitro quantitative potency assessment as an alternative to the Local Lymph Node Assay\nCome meet us at booth #333 and join our poster presentation to learn how the GARD assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment\, providing a high performing and ethical alternative to animal testing. \n→ Joint poster with Takasago\nQuantitative potency assessment of skin sensitizers when developing novel fragrance ingredients\nPractical application of the GARDskin Dose-Response assay to derive a No Expected Sensitization Induction Level (NESIL) value for confirmatory human patch studies to determine safe use level for novel fragrance ingredients \n→ Hot topic\nIn vitro tests supporting Occupational Health\nOccupational allergic dermatitis and asthma are common workplace diseases. By using the in vitro GARD® assays to test for skin and respiratory sensitizers in combination\, it is possible to identify allergens in the work environment and take preventive action. \nCome by our booth to learn more! \n→ Discuss your toxicological risk assessment needs with us!\nMeet our in vitro experts\, Dr Andy Forreryd and Dr Tim Lindberg
URL:https://senzagen.com/event/act-2023-annual-meeting/
LOCATION:Orlando\, Florida\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/banner_ACT2023-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231018T160000
DTEND;TZID=Europe/Stockholm:20231018T170000
DTSTAMP:20260429T205900
CREATED:20231002T134126Z
LAST-MODIFIED:20231002T155151Z
UID:31216-1697644800-1697648400@senzagen.com
SUMMARY:Webinar: Latest GARD® innovation and research in in vitro skin and respiratory sensitization
DESCRIPTION:We invite you to participate in our webinar where new cutting edge GARD results will be explained by the experts at SenzaGen and our partners.\nIn case you missed SenzaGen’s Scientific Posters and Oral Presentations at this year’s WC12 in Niagara Falls or Eurotox in Ljubljana\, we are pleased to offer you a new opportunity to participate on Oct 18\, 2023! \nCome and join us to explore the most recent GARD® data on skin sensitization\, presented by Emily N Reinke from Inotiv-RTP\, a project done in collaboration with NIH and Burleson Research Technologies. \nAdditionally\, we will showcase our most recent collaborative projects with industry partners: \nMerck| Johnson Matthey | Corteva Agriscience | ExxonMobil Biomedical Sciences | International Flavors & Fragrances (IFF) | Duearity | Inotiv-RTP \n  \n \n  \nKey topics \n\nDifficult-to-Test Samples\nUVCBs and Formulated Lubricant Products\nAgrochemical Formulations\nComplex Mixtures\nMetals\nQuantitative Potency Assessments\nRegulatory Acceptance According to MDR\nProtein Allergens\n\n  \nSpeakers \n \n  \nRegister here \n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.\n\n 
URL:https://senzagen.com/event/webinar-latest-gard-innovation-and-research-in-in-vitro-skin-and-respiratory-sensitization/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/10/Lime_webinarium_WC12-and-2023-Eurotox-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230913
DTEND;VALUE=DATE:20230914
DTSTAMP:20260429T205900
CREATED:20230823T145738Z
LAST-MODIFIED:20230823T145738Z
UID:30926-1694563200-1694649599@senzagen.com
SUMMARY:The Fragrance Science & Advocacy Council (FSAC) In-person Workshop
DESCRIPTION:Dermal Sensitizers: A Workshop on State of the Science and Utilization of New Approach Methodologies for Quantitative Risk Assessment\n 
URL:https://senzagen.com/event/the-fragrance-science-advocacy-council-fsac-in-person-workshop/
LOCATION:Arlington\, Virginia\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/08/FSAC-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230910T080000
DTEND;TZID=Europe/Stockholm:20230923T170000
DTSTAMP:20260429T205900
CREATED:20230313T144734Z
LAST-MODIFIED:20230831T110511Z
UID:30473-1694332800-1695488400@senzagen.com
SUMMARY:Eurotox 2023
DESCRIPTION:New opportunities for skin sensitization testing with GARD®skin OECD TG 442E\nCome meet us at booth #36 and join our poster presentations to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development.\nMeet also ToxHub\, our latest addition to the Group\, and benefit from expert Toxicology and Regulatory advice.\nBooth #36\n\nDiscuss your toxicological risk assessment needs with us!\n\n \n \nPosters\n\nSpotlight on Difficult-to-Test\, Quantitative Potency\, Medical Devices and E&L Assessment\n\n→ Joint poster with Exxon Mobil\nP07-02 | Assessing the utility of the Genomic Allergen Rapid Detection (GARD®skin) assay to detect dermal sensitization potential in UVCBs and formulated lubricant products \n→ Joint poster with IFF and RIFM\nP22-43 | The GARD® skin Dose-Response assay for determination of a point-of-departure (PoD) for Next Generation Risk Assessment (NGRA) of skin sensitizers: A case study using isocyclocitral \n→ Joint poster with Duearity\nP22-30 | Regulatory approval of medical devices according to MDR using in vitro data from GARD® skin Medical Device for skin sensitization assessment \n→ ToxHub poster\nLP-38 | Toxicological risk assessment of extractable and leachable compounds: mitigating risks in pharmaceutical applications \nNew\n\nTailored Toxicology Services\n\nAt our booth\, you will also meet our independent consultancy unit Toxhub\, specialized in toxicological risk assessment and regulatory strategy consulting\, with expertise in pharmaceuticals\, chemicals\, medical devices and cosmetics. \nExplore ToxHub’s services \n 
URL:https://senzagen.com/event/eurotox-congress-2023/
LOCATION:Ljubljana\, Slovenia\, Slovenia
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/03/Eurotox23v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230910
DTEND;VALUE=DATE:20230914
DTSTAMP:20260429T205900
CREATED:20230823T144809Z
LAST-MODIFIED:20230824T070750Z
UID:30921-1694304000-1694649599@senzagen.com
SUMMARY:Occupational Toxicology Roundtable 2023
DESCRIPTION:
URL:https://senzagen.com/event/occupational-toxicology-roundtable-2023/
LOCATION:Cleveland\, Ohio\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/08/OTR2023.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230831T080000
DTEND;TZID=Europe/Stockholm:20230904T170000
DTSTAMP:20260429T205900
CREATED:20230313T144259Z
LAST-MODIFIED:20230831T105454Z
UID:30467-1693468800-1693846800@senzagen.com
SUMMARY:WC12
DESCRIPTION:12th World Congress on Alternatives and Animal Use in the Life Sciences\nOur team and partners will feature the GARD® assays in several posters and presentations. Join us to explore new scientific data and exciting projects done in collaboration with industry partners.\nSymposia\n\nSpotlight on Medical Devices\, Complex Samples and Dose-Response\n\nWednesday\, Aug 30\, 11:00 – 12:30\, Session S410\n→ In collaboration with Duearity\n#515 Application of the GARD®skin Medical Device assay for regulatory approval of medical devices according to MDR \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ In collaboration with RIFM and IFF\n#208 In vitro determination of a point of departure for Next Generation Risk Assessment (NGRA) of skin sensitizers: Reproducibility and precision of the GARD®skin Dose-Response assay \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ Presented by Emily N Reinke\, Inotiv-RTP\, in collaboration with NIH and Burleson Research Technologies\n#90 Evaluating Skin Sensitization Hazard of Diverse Chemicals Using GARD®skin \nPosters\n\nSpotlight on Complex Mixtures\, Metals and Protein Allergens\n\nTuesday\, Aug 29\, 12:30 – 14:00\n→ Joint poster with Corteva Agriscience\nA33 #230 | GARD®: a study to investigate the applicability domain for agrochemical formulations \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Johnson Matthey\nF81 #55 | Expanding the applicability domain of NAMs for skin sensitization testing: a case study using GARD®skin for assessment of metals \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Merck\nF80 #498 | Characterization of respiratory sensitizing properties of the protein Subtilisin\, using GARD®air \nMeet our team\n\nMeet and greet with Andy Forreryd
URL:https://senzagen.com/event/12th-world-congress-on-alternatives-and-animal-use-in-the-life-sciences-wc12/
LOCATION:Niagara Falls\, Canada\, Niagara Falls\, Canada
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Number-logo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230622
DTSTAMP:20260429T205900
CREATED:20230607T072453Z
LAST-MODIFIED:20230607T072928Z
UID:30813-1687219200-1687391999@senzagen.com
SUMMARY:MedTech Summit 2023
DESCRIPTION:Biocompatibility for Medical Devices\nTuesday\, 20 June 2023 12:00 – 12:30 \n\nThe GARDskin Medical Device assay for assessing the skin sensitizing potential of medical devices: A case study on the use of in vitro data in the biological evaluation for CE marking according to MDR\n\n\nA proof-of-concept study using the GARDskin Medical Device assay to evaluate the skin sensitizing potential of medical device materials using both polar and non-polar extraction vehicles (ISO 10993-12).\nA case study using in vitro data for the endpoints of cytotoxicity\, skin irritation and skin sensitization in the biological evaluation for CE-marking according to MDR to avoid animal testing while accelerating time to market\n\nSpeaker \n\n\nDr Andy Forreryd\nScientific Liason at SenzaGen
URL:https://senzagen.com/event/medtech-summit-2023/
LOCATION:Brussels\, Belgium
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/06/MedTechSummit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230615
DTEND;VALUE=DATE:20230616
DTSTAMP:20260429T205900
CREATED:20230602T121642Z
LAST-MODIFIED:20230607T084110Z
UID:30803-1686787200-1686873599@senzagen.com
SUMMARY:Skin Sensitization by Altertox Academy
DESCRIPTION:This two days hands-on training is hosted by acCELLerate. \nSkin sensitization is a complex systemic process and since several years\, methods to replace animal tests have been validated and adopted by the OECD in this regard. These tests can be used as part of a weight-of-evidence or integrated using a Defined Approach (DA) to assess Skin Sensitization. \nAgenda\n09:55-10:25 GARD\, SenzaGen\n13:30-14:30 GARD – Case studies\, SenzaGen \nRegistration fee includes the participant booklet\, catering and social dinner. \nRegister here \n 
URL:https://senzagen.com/event/skin-sensitization-by-altertox-academy/
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/06/square-accellerate-2023.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230612T160000
DTEND;TZID=Europe/Stockholm:20230612T170000
DTSTAMP:20260429T205900
CREATED:20230524T114652Z
LAST-MODIFIED:20230524T114819Z
UID:30777-1686585600-1686589200@senzagen.com
SUMMARY:Webinar: Time for a Change: Evidence-Based Approaches for the Biological Safety Assessment of Medical Devices
DESCRIPTION:Join this free webinar where Ron Brown\, toxicologist and former FDA risk assessor\, will outline the need for a new and more agile approach for the biological safety assessment of medical devices.\nThis presentation will identify the limitations associated with the current approach\, which largely relies on animal-based tests that may have questionable clinical relevance. It will also describe how new and existing biocompatibility test methods can be evaluated following the principles of an evidence-based toxicology (EBT).\nYou will also learn how to incorporate New Approach Methodologies (NAMs) into a streamlined workflow for the safety assessment of medical devices\, which may decrease the time needed for regulatory approval of a device.\n \nKey takeaways \n\nThe limitations associated with animal-based approaches used to assess the biological safety of medical devices.\nHow to assess the validity of NAMs by using an evidence-based toxicology (EBT) approach.\nHow to incorporate NAMs into a streamlined workflow for medical device safety assessment.\nA case study on the OECD approval of the in vitro assay GARDskin and its applicability for Medical Device assessments supporting both polar and non-polar extraction vehicles (ISO 10993-12).\n\nSpeakers \n \n\nRegister here \n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.
URL:https://senzagen.com/event/webinar-time-for-a-change-evidence-based-approaches-for-the-biological-safety-assessment-of-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/Lime_webinarium_12-JUNE.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230524T160000
DTEND;TZID=Europe/Stockholm:20230524T170000
DTSTAMP:20260429T205900
CREATED:20230510T075904Z
LAST-MODIFIED:20230511T080404Z
UID:30647-1684944000-1684947600@senzagen.com
SUMMARY:Webinar: Using in vitro data in your CE marking submission of Medical Devices
DESCRIPTION:Join this free webinar to learn how you can avoid animal testing and accelerate time to market by using results from in vitro testing for the endpoints of cytotoxicity\, skin irritation and skin sensitization in your biological evaluation for CE-marking of your medical device in line with the EU Medical Device Regulation 2017/745\, the MDR.\n\nKey takeaways \n\nAn introduction to how in vitro testing can be used in the biological evaluation of your medical device with focus on cytotoxicity\, skin irritation and skin sensitization according to MDR.\nThe unique and broad applicability of the OECD approved GARD® assay for skin sensitization testing\, supporting polar and non-polar extraction vehicles as recommended in ISO 10993-12.\nSeveral application examples and a class IIa product CE marking case study supporting ethical test solutions and faster time to market.\nExpert advisory and support in compilation of regulatory documentation for instance gap analysis of ISO standards\, Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER).\n\nSpeakers \n \n\nRegister here\n\n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.
URL:https://senzagen.com/event/webinar-using-in-vitro-data-in-your-ce-marking-submission-of-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/9maj_Lime-_ToxHub_banner_line-e1683643826658.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230513
DTEND;VALUE=DATE:20230514
DTSTAMP:20260429T205900
CREATED:20230511T074528Z
LAST-MODIFIED:20230511T075952Z
UID:30750-1683936000-1684022399@senzagen.com
SUMMARY:ISID 2023 Tokyo Satellite Meeting on Dermal Sensitization & Photoallergenicity
DESCRIPTION:This three-hour event kicks off with a welcome from Expert Panel for Fragrance Safety members Yoshiki Tokura\, MD\, PhD\, Donald V. Belsito\, MD\, and Magnus Bruce\, MD\, PhD\, and an introduction from RIFM’s President\, Anne Marie Api\, PhD\, ATS.\nSession \nDermal Sensitization & Photoallergenicity\n4:05-7:05 pm\, Saturday\, May 13\, 2023\nEminence Hall\, South Tower\, 5th Floor\, Keio Plaza Hotel\, Tokyo \n  \nSpeakers \nPresentations from international experts in toxicology and dermatology will include: \n\nMechanisms of Contact Dermatitis\, Kenji Kabashima\, MD\, PhD\, Kyoto Univ.\nRIFM Dermal Sensitization Program\, Isabelle Lee\, PhD\, RIFM\nOverview RIFM Photoallergy Research Program\, Gretchen Ritacco\, MS\, RIFM\nTrial for development of photo safety assessment system in Shiseido\, Shiho Oeda\, Shiseido\nRIFM-IIVS Photoallergy Research\, Allison Hilberer\, MS\, DABT\, IIVS\nRIFM-SenzaGen Photoallergy Research\, Andy Forreryd\, PhD\, SenzaGen
URL:https://senzagen.com/event/isid-2023-tokyo-satellite-meeting-on-dermal-sensitization-photoallergenicity/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/ISID.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230426T160000
DTEND;TZID=Europe/Stockholm:20230426T170000
DTSTAMP:20260429T205900
CREATED:20230328T144209Z
LAST-MODIFIED:20230330T133759Z
UID:30497-1682524800-1682528400@senzagen.com
SUMMARY:SOT2023 Recap Webinar
DESCRIPTION:In case you missed SenzaGen’s Scientific Session at this year’s SOT\, here is a new opportunity! \nTogether with guest speakers from ExxonMobil Biomedical Sciences Inc. and Research Institute for Fragrance Materials\, Inc. (RIFM)\, SenzaGen’s Andy Forreryd\, PhD will present the latest GARD® data on quantitative risk assessment and regulatory testing of skin sensitizers\, and the potential to further broaden the GARD® applicability. \n\nKey topics\n\n·        Quantitative potency assessments\n·        UVCBs and formulated lubricant products\n·        Agrochemical formulations\n·        Acrylate monomers\n·        Regulatory acceptance according to MDR\n·        New application: Photosensitization \n  \n\nSpeakers\n\nAssessing the Utility of the GARD®skin Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products  \nAllison Greminger\, PhD\, DABT\nToxicology Associate @ExxonMobil Biomedical Sciences Inc.\nDr. Greminger is a board-certified toxicologist who provides scientific and regulatory support to several ExxonMobil Product Solutions businesses. In her current position\, she reviews and evaluates toxicological data to support regulatory compliance for current products\, as well as guide new product development. Dr. Greminger has a specific interest in local hazards relevant for formulated products and has conducted various research on implementing non-animal testing strategies to inform hazard potential. \n  \nAn introduction to photosensitization and why there is a need for development of predictive assays capable of discriminating between photosensitization and photoirritancy \n\nGretchen Ritacco\nPrincipal toxicologist @Research Institute for Fragrance Materials\, Inc. (RIFM)\nGretchen Ritacco leads the Photosafety program at the Research Institute for Fragrance Materials (RIFM). Her duties include evaluating fragrance materials in support of RIFM’s Fragrance Ingredient Safety Assessments and managing RIFM’s photoallergy research. In addition\, she is engaged in collaborations with industry leaders to investigate new approaches to evaluate the photoallergenic potential of fragrance materials. Before RIFM\, Gretchen worked in the Allergy and Asthma Discovery Research group at Schering Plough Research Institute. She evaluated lead development candidates for treating pulmonary disorders\, refined measurement of allergic airway disease\, and investigated markers of airway inflammation. Gretchen is a member of the Society of Toxicology (SOT) and both the European and American Societies of Photobiology (ESP & ASP\, respectively). \n\n  \nNew GARD data on skin sensitization testing: “difficult-to-test” substances and quantitative potency assessment and regulatory testing of Medical Devices \n\n​Andy Forreryd\, PhD\nScientific Liaison @ SenzaGen\nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning. He is also co-developer of the GARD platform for the assessment of chemical sensitizers and is the inventor of two patents related to the technology. \n 
URL:https://senzagen.com/event/2023-sot-recap-webinar/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Lime_RECAP-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230322T080000
DTEND;TZID=Europe/Stockholm:20230323T170000
DTSTAMP:20260429T205900
CREATED:20221109T100611Z
LAST-MODIFIED:20230322T130845Z
UID:30088-1679472000-1679590800@senzagen.com
SUMMARY:2023 SOT Annual Meeting & ToxExpo
DESCRIPTION:Meet us at this year’s SOT\nCome meet us at our booth and join our hosted session to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development. \n \n  \n  \n\nExhibitor-Hosted Session\n\n\n  \n  \n\nPosters\n\n🎫 P117 |  Joint poster with ExxonMobil Biomedical Sciences\n#3016: Mar 20\, 9:00am-10:45am: Assessing the Utility of the Genomic Allergen Rapid Detection (GARDskin) Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products \n🎫 P329 | Joint poster with Research Institute for Fragrance Materials (RIFM)\n#4456: Mar 22\, 10:45am-12:30pm: GARDskin Dose-Response for Photosensitization: Assessment of Reference Photoirritants and Photoallergens \n🎫 P293 | Poster on Medical Device\n#4422: Mar 22\, 10:45am-12:30pm: In Vitro Assays for Assessment of Skin Sensitization Hazard and Potency of Isobornyl Acrylate \n🎫 P151 | Joint poster with International Flavors & Fragrances Inc. (IFF) and Research Institute for Fragrance Materials (RIFM)\n#5050: Mar 23\, 8:30am-11:30am: Gardskin Dose-Response Assay for Pod Determination of Fragrance Materials and Its Application in Conducting Quantitative Risk Assessment (QRA) \n\nExpanded toxicology testing services\n\nAt our booth\, we will introduce you to how you can use in vitro methods for the biological evaluation of medical devices and how we can support you with tailored toxicology advisory services. We will also present our expanded services for in vitro regulatory toxicity testing. \nFind out about our expanded services and expertise\n 
URL:https://senzagen.com/event/2023-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/Newsletter-banner-SOT.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230222T160000
DTEND;TZID=Europe/Stockholm:20230222T170000
DTSTAMP:20260429T205900
CREATED:20230131T145829Z
LAST-MODIFIED:20230131T150057Z
UID:30336-1677081600-1677085200@senzagen.com
SUMMARY:Webinar: Overcoming challenges in skin sensitization testing with GARDskin OECD TG 442E
DESCRIPTION:Free webinar on Feb 22\, 2023 | 4pm CET | 10am EST \nTogether with guest speakers Dr Marco Corvaro\, Technical Team Leader\, Regulatory Toxicology at Corteva Agriscience and Gretchen Ritacco\, Principal Scientist at the Research Institute for Fragrance Materials (RIFM)\, we will discuss the challenges in skin sensitization testing and present new scientific data on agrochemical formulations\, “difficult-to-test” substances\, potency assessment and the potential to further broaden the applicability of the GARD assay to assess the endpoint of photosensitization. \n  \n \n\nAgenda \n\nChallenges in skin sensitization assessment.\nUpdate on the recent OECD approval of GARD®skin TG 442E.\nCase studies on “difficult-to-test” substances and quantitative potency assessment.\nCase study: Investigating the applicability domain of GARD®skin and GARD®potency for agrochemical formulations. Presented by Dr Marco Corvaro\, Corteva Agrisciences.\nNew application: An introduction to photosensitization and why there is a need for development of predictive assays capable of discriminating between photosensitization and photoirritancy.\n\n  \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \nOvercoming challenges in skin sensitization testing with GARD®skin OECD TG 442E  \nThe field of skin sensitization assessment is rapidly evolving. New Approach Methodologies (NAMs) have been developed to increase predictivity\, broaden the applicability and to provide reliable quantitative and qualitative potency assessments. \nAs the first and only genomics and machine learning-based method\, GARDskin has been included into OECD Test Guideline 442E for in vitro skin sensitization. The scientific data published in the TG confirms the high performance and broad applicability of the method\, bringing new opportunities to the field of in vitro skin sensitization testing. \nPhototoxicity is a term used to describe chemicals which has the inherent potential to become photoactivated when exposed to UV-light\, giving rise to otherwise dormant adverse effects. Such effects may include both irritation and sensitization. In terms of risk management\, the distinction of the two types of chemicals is important\, as the hazardous exposure effects of photoirritants can be reduced by concentration limits\, whereas photoallergenic properties currently results in a ban of the chemical at hand. SenzaGen and the Research Institute for Fragrance Materials (RIFM) are collaborating to investigate and develop New Approach Methods (NAMs) for identification and discrimination of photosensitizers from photoirritants. Preliminary data from the incorporation of an UV-exposure step to the original protocol of GARDskin Dose-Response will be illustrated\, and the potential of this approach to simultaneously identify and distinguish between photosensitization and photoirritation will be discussed.  \n\nSpeakers \nDr Marco Covaro\nTechnical Team Leader\, Regulatory Toxicology at Corteva Agriscience\nDr Corvaro has more than 15 years of experience in the safety evaluation of regulated products in a variety of industry sectors. He is a European Registered Toxicologist (ERT) and works as technical lead in Regulatory Toxicology at Corteva. He also acts as the group focal point for activities in the 3R area\, including reduction and alternatives to animal toxicity testing and has been part of several technical expert groups at OECD\, EChA\, ECETOC\, EPAA\, CLE (previously ECPA and EuropaBio) aimed at scientific consensus building and science communication within the regulatory community. \nGretchen Ritacco\nPrincipal Scientist\, Dermatotoxicology at RIFM\nGretchen Ritacco leads the Photosafety program at the Research Institute for Fragrance Materials (RIFM). Her duties include evaluating fragrance materials in support of RIFM’s Fragrance Ingredient Safety Assessments and managing RIFM’s photoallergy research. In addition\, she is engaged in collaborations with industry leaders to investigate new approaches to evaluate the photoallergenic potential of fragrance materials. Before RIFM\, Gretchen worked in the Allergy and Asthma Discovery Research group at Schering Plough Research Institute. She evaluated lead development candidates for treating pulmonary disorders\, refined measurement of allergic airway disease\, and investigated markers of airway inflammation. Gretchen is a member of the Society of Toxicology (SOT) and both the European and American Societies of Photobiology (ESP & ASP\, respectively). \nDr Andy Forreryd\nScientific Liaison at SenzaGen\nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning. He is also co-developer of the GARD platform for the assessment of chemical sensitizers and is the inventor of two patents related to the technology. \n\nREGISTER NOW\n\n 
URL:https://senzagen.com/event/webinar-overcoming-challenges-in-skin-sensitization-testing-with-gardskin-oecd-tg-442e/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/Event-calendar_845x320.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230215
DTEND;VALUE=DATE:20230218
DTSTAMP:20260429T205900
CREATED:20230111T132555Z
LAST-MODIFIED:20230111T154919Z
UID:30279-1676419200-1676678399@senzagen.com
SUMMARY:PCHi 2023 Expo & SHSOT Forum
DESCRIPTION:Personal Care and Homecare Ingredients 2023 Expo & Shanghai Society of Toxicology Forum\n15-17 February 2023 @The China Import and Export Fair Complex\, Guangzhou\, China\nRead More
URL:https://senzagen.com/event/pchi-2023-expo-shsot-forum/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/msg98-1-2022-07-21-5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230209
DTEND;VALUE=DATE:20230210
DTSTAMP:20260429T205900
CREATED:20230112T112845Z
LAST-MODIFIED:20230112T114227Z
UID:30297-1675900800-1675987199@senzagen.com
SUMMARY:VitroScreen Seminar on Substance Based Medical Devices
DESCRIPTION:VitroScreen has been a pioneer in developing and proposing pre-clinical experimental protocols on 3D reconstructed human tissue models: they are currently applied to demonstrate the mechanism of action of SBMD and they are relevant to comply with the safety and efficacy requirements of the EU MDR 2017/745. \nThe seminar has the ambition to open a discussion on MDCG 2022-5 with stakeholders involved in Medical Devices (Health Authorities\, Notified Bodies\, Academia\, Industry and ISO representative) analyzing the state of the art of scientific approaches to qualification and classification issues. \nTo view the program and instruction for registration\, please\, click here.
URL:https://senzagen.com/event/vitroscreen-seminar-on-substance-based-medical-devices/
LOCATION:Excelsior Hotel Gallia\, Milan\, Italy
END:VEVENT
END:VCALENDAR